• 1
    UK Transplant. Transplant Activity in the UK 2002–03. Bristol , UK : NHS, 2003.
  • 2
    Eye Bank Association of America. 1994 Annual Report.
  • 3
    Darwin E. Zoonomia: or, the Law of Organic Life. Dublin : P Byrne & Jones W, 1796.
  • 4
    Bigger SLL. An enquiry into the possibility of transplanting the cornea, with the view of relieving blindness caused by several diseases of that structure. J Med Soc Dublin 1837; 11: 408417.
  • 5
    Kissam R. Ceratoplastice in man. N Y J Med 1844; 2: 281282.
  • 6
    Von Hippel A. Ein neue methode der hornhauttransplantation. Albrecht v Graefes. Arch Ophthalmol 1888; 34: 108130.
  • 7
    Zirm EK. Eine erfolgreiche totale keratopastik. J Refract Corneal Surg 1906; 5: 258161.
  • 8
    Archer DB, Trevor-Roper PD. Organization and administration of Westminster-Moorfields Eye-Bank. Br J Ophthalmol 1967; 51: 112.
  • 9
    Williams KA, Muehlberg SM, Lewis RF, Coster DJ. How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye 1995; 9: 219227.
  • 10
    Murphy C, Alvarado J, Juster R, Maglio M. Prenatal and postnatal cellularity of the human corneal endothelium. A quantitative histologic study. Invest Ophthalmol Vis Sci 1984; 25: 312322.
  • 11
    Joyce NC, Meklir B, Joyce SJ, Zieske JD. Cell cycle protein expression and proliferative status in human corneal cells. Invest Ophthalmol Vis Sci 1996; 37: 645655.
  • 12
    Bourne WM. Cellular changes in transplanted human corneas. Cornea 2001; 20: 560569.
  • 13
    Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci 2003; 44: 33263331.
  • 14
    Armitage WJ, Easty DL. Factors influencing the suitability of organ-cultured corneas for transplantation. Invest Ophthalmol Vis Sci 1997; 38: 1624.
  • 15
    Ing JJ, Ing HH, Nelson LR, Hodge DO, Bourne WM. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology 1998; 105: 18551865.
  • 16
    Joyce NC, Harris DL, Mello DM. Mechanisms of mitotic inhibition in corneal endothelium. contact inhibition and TGF-beta2. Invest Ophthalmol Vis Sci 2002; 43: 21522159.
  • 17
    Joyce NC, Harris DL, McAlister JC, Ali RR, Larkin DFP. Over-expression of the transcription factor E2F2 induces cell cycle progression in rabbit corneal endothelial cells. Invest Ophthalmol Vis Sci 2004 (in press).
  • 18
    Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ. Factors predictive of corneal graft survival. Report from the Australian Corneal Graft Registry. Ophthalmology 1992; 99: 403414.
  • 19
    Subramaniam S, Bunce C, Madison P et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 2001; 85: 14641469.
  • 20
    Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001; 108: 18381844.
  • 21
    Hill JC. The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989; 107: 506510.
  • 22
    The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 13921403.
  • 23
    Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation 1994; 58: 12101216.
  • 24
    Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol 1999; 83: 13481352.
  • 25
    Larkin DF, Alexander RA, Cree IA. Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye 1997; 11: 6874.
  • 26
    Torres PFV-AF, D G-R, Martins B, Kijlstra A. Cytokine mRNA expression during experimental corneal allograft rejection. Exp Eye Res 1996; 63: 453461.
  • 27
    Rayner SA, King WJ, Comer RM et al. Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation. Clin Exp Immunol 2000; 122: 109116.
  • 28
    King WJ, Comer RM, Hudde T, Larkin DFP, George AJT. Cytokine and chemokine expression kinetics following corneal transplantation. Transplantation 2000; 70: 12251233.
  • 29
    Chan CC, Stark J, George AJ. Analysis of cytokine dynamics in corneal allograft rejection. Proc R Soc Lond B Biol Sci 1999; 266: 22172223.
  • 30
    Larkin DFP, Calder VL, Lightman SL. Identification and characterisation of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol 1996; 107: 381391.
  • 31
    He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991; 32: 27232728.
  • 32
    Nicholls SM, Bradley BB, Easty DL. Effect of mismatches for major histocompatibility complex and minor antigens on corneal graft rejection. Invest Ophthalmol Vis Sci 1991; 32: 27292734.
  • 33
    Streilein JW, Toews GB, Bergstresser PR. Corneal allografts fail to express Ia antigens. Nature 1979; 282: 326327.
  • 34
    Arancibia-Cárcamo CV, Osawa H, Arnett HA et al. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites. Eur J Immunol 2004; 34: 471480.
  • 35
    Hahn AB, Foulks GN, Enger C et al. The association of lymphocytotoxic antibodies with corneal allograft rejection in high risk patients. The Collaborative Corneal Transplantation Studies Research Group. Transplantation 1995; 59: 2127.
  • 36
    Jager MJ, Vos A, Pasmans S, Hoekzema R, Broersma L, Van Der Gaag R. Circulating cornea-specific antibodies in corneal disease and cornea transplantation. Graefes Arch Clin Exp Ophthalmol 1994; 232: 8286.
  • 37
    Grunnet N, Kristensen T, Kissmeyer-Nielsen F, Ehlers N. Occurrence of lymphocytotoxic lymphocytes and antibodies after corneal transplantation. Acta Ophthalmol (Copenh) 1976; 54: 16773.
  • 38
    Hegde S, Mellon JK, Hargrave SL, Niederkorn JY. Effect of alloantibodies on corneal allograft survival. Invest Ophthalmol Vis Sci 2002; 43: 10121018.
  • 39
    Slegers TP, Torres PF, Broersma L, Van Rooijen N, Van Rij G, Van Der Gaag R. Effect of macrophage depletion on immune effector mechanisms during corneal allograft rejection in rats. Invest Ophthalmol Vis Sci 2000; 41: 22392247.
  • 40
    Streilein JW. Regional immunity and ocular immune privilege. Chem Immunol 1999; 73: 1138.
  • 41
    Niederkorn JY. The immune privilege of corneal allografts. Transplantation 1999; 67: 15031508.
  • 42
    Williams KA, Coster DJ. Rethinking immunological privilege: implications for corneal and limbal stem cell transplantation. Mol Med Today 1997; 3: 495501.
  • 43
    Medawar PB. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29: 5869.
  • 44
    Ross J, He YG, Pidherney M, Mellon J, Niederkorn JY. The differential effects of donor versus host Langerhans cells in the rejection of MHC-matched corneal allografts. Transplantation 1991; 52: 857861.
  • 45
    Liu Y, Hamrah P, Zhang Q, Taylor AW, Dana MR. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J Exp Med 2002; 195: 259268.
  • 46
    Hamrah P, Zhang Q, Liu Y, Dana MR. Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002; 43: 639646.
  • 47
    Brissette-Storkus CS, Reynolds SM, Lepisto AJ, Hendricks RL. Identification of a novel macrophage population in the normal mouse corneal stroma. Invest Ophthalmol Vis Sci 2002; 43: 22642271.
  • 48
    Streilein JW, Niederkorn JY, Shadduck JA. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J Exp Med 1980; 152: 11211125.
  • 49
    Niederkorn JY. Anterior chamber-associated immune deviation. Chem Immunol 1999; 73: 5971.
  • 50
    Sonoda KH, Stein-Streilein J. Ocular immune privilege and CD1d-reactive natural killer T cells. Cornea 2002; 21: S33–S38.
  • 51
    Sonoda KH, Faunce DE, Taniguchi M, Exley M, Balk S, Stein-Streilein J. NK T cell-derived IL-10 is essential for the differentiation of antigen-specific T regulatory cells in systemic tolerance. J Immunol 2001; 166: 4250.
  • 52
    Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 11891192.
  • 53
    Yamagami S, Kawashima H, Tsuru T et al. Role of Fas–Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64: 11071111.
  • 54
    Stuart PM, Griffith TS, Usui N, Pepose J, YuX. Ferguson TA. CD95 ligand (FasL) -induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99: 396402.
  • 55
    Dana MR, Yamada J, Streilein JW. Topical interleukin 1 receptor antagonist promotes corneal transplant survival. Transplantation 1997; 63: 15011507.
  • 56
    Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002; 43: 10951103.
  • 57
    Ardjomand N, McAlister JC, Rogers NJ, Tan PH, George AJ, Larkin DF. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection. Invest Ophthalmol Vis Sci 2003; 44: 38993905.
  • 58
    Larkin DFP, Oral HB, Ring CJA, Lemoine NR, George AJT. Adenovirus-mediated gene delivery to the corneal endothelium. Transplantation 1996; 61: 363370.
  • 59
    Hudde T, Rayner SA, De Alwis M et al. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea 2000; 19: 369205.
  • 60
    George AJT, Arancibia-Cárcamo CV, Awad HM et al. Gene delivery to the corneal endothelium. Am J Respir Crit Care Med 2000; 162: S194S200.
  • 61
    Oral HB, Larkin DFP, Fehervari Z et al. Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther 1997; 4: 639647.
  • 62
    Fehervari Z, Rayner SA, Oral HB, George AJT, Larkin DFP. Gene transfer to ex vivo stored corneas. Cornea 1997; 16: 459464.
  • 63
    Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71: 12141220.
  • 64
    Rayner SA, Larkin DFP, George AJT. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001; 42: 15681573.
  • 65
    Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk HD, Ritter T. Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol 2000; 238: 531536.
  • 66
    Tan PH, King WJ, Chen D et al. Transferrin receptor mediated gene transfer to the corneal endothelium. Transplantation 2001; 71: 552560.
  • 67
    Tan PH, Manunta M, Ardjomand N et al. Antibody targeted gene transfer to endothelium. J Gene Med 2003; 5: 311323.
  • 68
    Hudde T, Rayner SA, Comer RM et al. Activated polyamidoamine dendrimers, a non viral vector for gene transfer to the corneal endothelium. Gene Ther 1998; 6: 939943.
  • 69
    Larkin DF. Corneal allograft rejection. Br J Ophthalmol 1994; 78: 649652.